These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 11367132

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The great salvage therapy drug juggle.
    Cadman J.
    GMHC Treat Issues; 1998 Apr; 12(4):1-6. PubMed ID: 11365398
    [Abstract] [Full Text] [Related]

  • 7. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V, Descamps D, Yeni P.
    AIDS Rev; 2002 Apr; 4(3):128-39. PubMed ID: 12416447
    [Abstract] [Full Text] [Related]

  • 8. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V, Red de Investigación en SIDA.
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J, Souyris C, Sandres-Sauné K, Puissant B, Obadia M, Pasquier C, Puel J, Blancher A, Massip P.
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 16. More trouble for adefovir.
    Gilden D.
    GMHC Treat Issues; 1999 Apr; 13(4):3. PubMed ID: 11366975
    [Abstract] [Full Text] [Related]

  • 17. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG.
    AIDS; 2009 Jul 31; 23(12):1605-8. PubMed ID: 19487903
    [Abstract] [Full Text] [Related]

  • 18. Salvage therapies get attention at conference.
    Rodriguez E.
    Posit Living; 1999 Nov 31; 8(10):6, 45, 47. PubMed ID: 11367335
    [Abstract] [Full Text] [Related]

  • 19. Salvage therapy: still more intuition than data.
    Gilden D.
    GMHC Treat Issues; 1999 Jan 31; 13(1):6-12. PubMed ID: 11366112
    [Abstract] [Full Text] [Related]

  • 20. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
    Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN.
    J Infect Dis; 2005 Nov 01; 192(9):1537-44. PubMed ID: 16206068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.